MXPA04005990A - Derivados de 5,6-diaril-pirazina-2-amida como antagonistas de cb1. - Google Patents
Derivados de 5,6-diaril-pirazina-2-amida como antagonistas de cb1.Info
- Publication number
- MXPA04005990A MXPA04005990A MXPA04005990A MXPA04005990A MXPA04005990A MX PA04005990 A MXPA04005990 A MX PA04005990A MX PA04005990 A MXPA04005990 A MX PA04005990A MX PA04005990 A MXPA04005990 A MX PA04005990A MX PA04005990 A MXPA04005990 A MX PA04005990A
- Authority
- MX
- Mexico
- Prior art keywords
- group
- 3alkyl
- optionally substituted
- mono
- optionally
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Addiction (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invencion se refiere a compuestos de la formula (I), y las sales farmaceuticamente aceptables, profarmacos, solvatos y formas cristalinas de los mismos, en los cuales R1 y R2 independientemente representan: un grupo de alquilo de C1 - C6, o un grupo de alquil de C1 - C6 (amino), un grupo carboxilico de C3 - C19 no aromatico opcionalmente substituido, un grupo de cicloalquilo de C3 - C12alquilo de C1 - C3, un grupo - (CH2) ? (fenilo) s, en donde r es 0, 1, 2, 3, o 4, s es 1, cuando r es 1 o 2, y los grupos de fenilo estan opcionalmente e independientemente substituidos por z; naftilo, antracenilo; un grupo heterociclico de 5 a 8 miembros saturado opcionalmente substituido que contiene un atomo de nitrogeno y opcionalmente uno de los siguientes; oxigeno, azufre o un nitrogeno adicional, 1-adamantilmetilo; un grupo -(CH2) tHet, en donde t wa 0, 1, 2, 3, o 4 y la cadena de alquileno esta opcionalmente substituida y Het representa un heterociclo aromatico opcionalmente substituido, o R1 representa H y R2 es como se ha definido antes; o R1 y R2 juntos con el atomo de nitrogeno al cual, se unen representan un grupo heterociclico de 5 a 8 miembros substituido opcionalmente saturado, como se ha definido antes; X es CO o SO2; Y esta ausente o representa NH opcionalmente substituido por un grupo de alquilo de alquilo de C1 - C3 ; R3 y R4 independientemente representan fenilo, tienilo o piridilo substituidos por Z; Z representa un grupo de alquilo de C1 - C3, un grupo de alcoxi de C1 - C3, un grupo de alcoxi de C1 - C3, hidroxi, halo, trifluorometilo, trifluoroetiltio, trifluorometoxi, trifluorometilo, trifluorometilsulfonilo, nitro, amino, mono o dialquilamino de C1 - C3, mono - o di - alquilamino de C1 - C3, alquilsulfonilo de C1 - C3, alcoxicarbonilo de C1 - C3, carboxi, ciano carbamoilo, mono o dialquilcarbomoilo de C1 - C3, sulfamoilo y acetilo; y R5 es H, un grupo de alcoximetilo de C1 - C3, trifluorometilo, un grupo de hidroxialquilo de C1 - C3, alcoxicarbonilo de C1 - C3, carboxi, ciano, carbamoilo, mono - dialquilcarbamoilo de C1 - C3, acetilo, o hidrazinocarbonilo de la formula -CONHNRaRb, con la condicion; y al procedimiento para la preparacion de tales compuestos, su uso en el tratamiento de la obesidad, desordenes siquiatricas y neurologicos, a los metodos para su uso terapeutico, y a las composiciones farmaceuticas que contienen a los mismos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0104330A SE0104330D0 (sv) | 2001-12-19 | 2001-12-19 | Therapeutic agents |
| PCT/GB2002/005742 WO2003051851A1 (en) | 2001-12-19 | 2002-12-18 | 5, 6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA04005990A true MXPA04005990A (es) | 2004-09-27 |
Family
ID=20286429
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA04005990A MXPA04005990A (es) | 2001-12-19 | 2002-12-18 | Derivados de 5,6-diaril-pirazina-2-amida como antagonistas de cb1. |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US7342019B2 (es) |
| EP (1) | EP1458690B1 (es) |
| JP (1) | JP2005517655A (es) |
| KR (1) | KR20040068286A (es) |
| CN (1) | CN1620438A (es) |
| AR (1) | AR038044A1 (es) |
| AT (1) | ATE354570T1 (es) |
| AU (1) | AU2002352425A1 (es) |
| BR (1) | BR0214989A (es) |
| CA (1) | CA2469786A1 (es) |
| CO (1) | CO5590917A2 (es) |
| DE (1) | DE60218340T2 (es) |
| ES (1) | ES2280599T3 (es) |
| HU (1) | HUP0402026A3 (es) |
| IL (1) | IL162377A0 (es) |
| IS (1) | IS7314A (es) |
| MX (1) | MXPA04005990A (es) |
| NO (1) | NO20043022L (es) |
| NZ (1) | NZ533275A (es) |
| PL (1) | PL369731A1 (es) |
| RU (1) | RU2004116916A (es) |
| SE (1) | SE0104330D0 (es) |
| TW (1) | TW200410694A (es) |
| WO (1) | WO2003051851A1 (es) |
| ZA (1) | ZA200404805B (es) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7704995B2 (en) | 2002-05-03 | 2010-04-27 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| GB0216700D0 (en) | 2002-07-18 | 2002-08-28 | Astrazeneca Ab | Process |
| WO2004029204A2 (en) | 2002-09-27 | 2004-04-08 | Merck & Co., Inc. | Substituted pyrimidines |
| US7129239B2 (en) | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
| US7247628B2 (en) | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| GB0230088D0 (en) * | 2002-12-24 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
| GB0302671D0 (en) * | 2003-02-06 | 2003-03-12 | Astrazeneca Ab | Pharmaceutical formulations |
| GB0302673D0 (en) * | 2003-02-06 | 2003-03-12 | Astrazeneca Ab | Pharmaceutical formulations |
| US7176210B2 (en) | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| US7141669B2 (en) | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
| US7268133B2 (en) | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
| US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| JP2006527770A (ja) * | 2003-06-18 | 2006-12-07 | アストラゼネカ アクチボラグ | Ｃｂ１モジュレーターとしての２−置換５，６−ジアリール−ピラジン誘導体 |
| GB0314049D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| GB0314057D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| GB0314261D0 (en) * | 2003-06-19 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| US20050014786A1 (en) | 2003-07-11 | 2005-01-20 | Chongqing Sun | Tetrahydroquinoline derivatives as cannabinoid receptor modulators |
| US7326706B2 (en) | 2003-08-15 | 2008-02-05 | Bristol-Myers Squibb Company | Pyrazine modulators of cannabinoid receptors |
| WO2005020992A1 (en) * | 2003-09-02 | 2005-03-10 | Solvay Pharmaceuticals Gmbh | Novel medical use of selective cb1-receptor antagonists |
| US7320805B2 (en) * | 2003-10-01 | 2008-01-22 | Institut National De La Sante Et De La Recherche Medicale | CB2 receptors blocks accumulation of human hepatic myofibroblasts: a novel artifibrogenic pathway in the liver |
| WO2005037199A2 (en) | 2003-10-10 | 2005-04-28 | Bristol-Myers Squibb Company | Pyrazole derivatives as cannabinoid receptor modulators |
| TW200528102A (en) * | 2003-10-24 | 2005-09-01 | Solvay Pharm Gmbh | Novel medical combination treatment of obesity involving 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
| WO2005039579A1 (en) * | 2003-10-24 | 2005-05-06 | Solvay Pharmaceuticals Gmbh | Combination treatment of obesity involving selective cb1-antagonists and lipase inhibitors |
| GB0327331D0 (en) * | 2003-11-25 | 2003-12-31 | Astrazeneca Ab | Therapeutic agents |
| US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
| TW200602314A (en) | 2004-05-28 | 2006-01-16 | Tanabe Seiyaku Co | A novel pyrrolidine compound and a process for preparing the same |
| BRPI0517434A (pt) | 2004-10-25 | 2008-10-07 | Solvay Pharm Gmbh | composições farmacêuticas compreendendo antagonistas do receptor canabinóide cb1 e abridores de canal de potássio para o tratamento de diabetes mellitus do tipo i, obesidade e estados relacionados |
| WO2006106054A1 (en) | 2005-04-06 | 2006-10-12 | F. Hoffmann-La Roche Ag | Pyridine-3-carboxamide derivatives as cb1 inverse agonists |
| US20070078135A1 (en) * | 2005-04-18 | 2007-04-05 | Neurogen Corporation | Substituted heteroaryl CB1 antagonists |
| AU2006264649A1 (en) | 2005-06-30 | 2007-01-11 | Prosidion Limited | GPCR agonists |
| US7629346B2 (en) | 2006-06-19 | 2009-12-08 | Hoffmann-La Roche Inc. | Pyrazinecarboxamide derivatives as CB1 antagonists |
| US7781593B2 (en) | 2006-09-14 | 2010-08-24 | Hoffmann-La Roche Inc. | 5-phenyl-nicotinamide derivatives |
| AU2007304365A1 (en) * | 2006-10-04 | 2008-04-10 | F. Hoffmann-La Roche Ag | 3-pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as HDL-cholesterol raising agents |
| EA016507B1 (ru) | 2007-01-04 | 2012-05-30 | Прозидион Лимитед | Пиперидиновые агонисты gpcr |
| EP2114933B1 (en) | 2007-01-04 | 2011-09-07 | Prosidion Ltd | Piperidine gpcr agonists |
| GB0700122D0 (en) | 2007-01-04 | 2007-02-14 | Prosidion Ltd | GPCR agonists |
| PE20081849A1 (es) | 2007-01-04 | 2009-01-26 | Prosidion Ltd | Derivados de piperidin-4-il-propoxi-benzamida como agonistas de gpcr |
| AR064735A1 (es) | 2007-01-04 | 2009-04-22 | Prosidion Ltd | Agonistas de gpcr y composicion farmaceutica en base al compuesto |
| GB0720390D0 (en) | 2007-10-18 | 2007-11-28 | Prosidion Ltd | G-Protein coupled receptor agonists |
| GB0720389D0 (en) | 2007-10-18 | 2008-11-12 | Prosidion Ltd | G-Protein Coupled Receptor Agonists |
| WO2010079241A1 (es) | 2009-01-12 | 2010-07-15 | Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion | Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas |
| US8410107B2 (en) | 2010-10-15 | 2013-04-02 | Hoffmann-La Roche Inc. | N-pyridin-3-yl or N-pyrazin-2-yl carboxamides |
| US8669254B2 (en) | 2010-12-15 | 2014-03-11 | Hoffman-La Roche Inc. | Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents |
| US9403808B2 (en) * | 2011-10-28 | 2016-08-02 | Hoffmann-La Roche Inc. | Pyrazine derivatives |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH458361A (de) * | 1965-01-15 | 1968-06-30 | Eprova Ag | Verfahren zur Herstellung von Pyrazincarbonsäuren |
| JPS5322529A (en) * | 1976-08-13 | 1978-03-02 | Nippon Soda Co Ltd | Dihydropyrazine derivative and its preparation |
| EP0397859A4 (en) * | 1987-11-12 | 1990-12-19 | Terumo Kabushiki Kaisha | Pyrazine derivatives and medicinal preparation containing same |
| WO1992002513A1 (en) | 1990-08-06 | 1992-02-20 | Fujisawa Pharmaceutical Co., Ltd. | Heterocyclic compounds |
| FR2713225B1 (fr) * | 1993-12-02 | 1996-03-01 | Sanofi Sa | N-pipéridino-3-pyrazolecarboxamide substitué. |
-
2001
- 2001-12-19 SE SE0104330A patent/SE0104330D0/xx unknown
-
2002
- 2002-12-18 HU HU0402026A patent/HUP0402026A3/hu unknown
- 2002-12-18 JP JP2003552736A patent/JP2005517655A/ja active Pending
- 2002-12-18 NZ NZ533275A patent/NZ533275A/en unknown
- 2002-12-18 MX MXPA04005990A patent/MXPA04005990A/es unknown
- 2002-12-18 ES ES02788143T patent/ES2280599T3/es not_active Expired - Lifetime
- 2002-12-18 AT AT02788143T patent/ATE354570T1/de not_active IP Right Cessation
- 2002-12-18 CA CA002469786A patent/CA2469786A1/en not_active Abandoned
- 2002-12-18 WO PCT/GB2002/005742 patent/WO2003051851A1/en active IP Right Grant
- 2002-12-18 EP EP02788143A patent/EP1458690B1/en not_active Expired - Lifetime
- 2002-12-18 RU RU2004116916/04A patent/RU2004116916A/ru not_active Application Discontinuation
- 2002-12-18 IL IL16237702A patent/IL162377A0/xx unknown
- 2002-12-18 US US10/499,054 patent/US7342019B2/en not_active Expired - Fee Related
- 2002-12-18 AU AU2002352425A patent/AU2002352425A1/en not_active Abandoned
- 2002-12-18 PL PL02369731A patent/PL369731A1/xx not_active Application Discontinuation
- 2002-12-18 KR KR10-2004-7009589A patent/KR20040068286A/ko not_active Application Discontinuation
- 2002-12-18 CN CNA028281535A patent/CN1620438A/zh active Pending
- 2002-12-18 BR BR0214989-3A patent/BR0214989A/pt not_active IP Right Cessation
- 2002-12-18 DE DE60218340T patent/DE60218340T2/de not_active Expired - Fee Related
- 2002-12-19 AR ARP020105001A patent/AR038044A1/es not_active Application Discontinuation
- 2002-12-19 TW TW091136671A patent/TW200410694A/zh unknown
-
2004
- 2004-06-16 IS IS7314A patent/IS7314A/is unknown
- 2004-06-17 ZA ZA200404805A patent/ZA200404805B/en unknown
- 2004-07-09 CO CO04065292A patent/CO5590917A2/es not_active Application Discontinuation
- 2004-07-15 NO NO20043022A patent/NO20043022L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| DE60218340D1 (de) | 2007-04-05 |
| NZ533275A (en) | 2006-02-24 |
| CA2469786A1 (en) | 2003-06-26 |
| IS7314A (is) | 2004-06-16 |
| EP1458690B1 (en) | 2007-02-21 |
| HUP0402026A2 (hu) | 2005-02-28 |
| SE0104330D0 (sv) | 2001-12-19 |
| NO20043022L (no) | 2004-07-15 |
| AR038044A1 (es) | 2004-12-22 |
| TW200410694A (en) | 2004-07-01 |
| CO5590917A2 (es) | 2005-12-30 |
| CN1620438A (zh) | 2005-05-25 |
| US20050032808A1 (en) | 2005-02-10 |
| EP1458690A1 (en) | 2004-09-22 |
| JP2005517655A (ja) | 2005-06-16 |
| PL369731A1 (en) | 2005-05-02 |
| ATE354570T1 (de) | 2007-03-15 |
| HUP0402026A3 (en) | 2005-08-29 |
| BR0214989A (pt) | 2004-12-14 |
| RU2004116916A (ru) | 2005-11-10 |
| US7342019B2 (en) | 2008-03-11 |
| WO2003051851A1 (en) | 2003-06-26 |
| ZA200404805B (en) | 2005-08-15 |
| IL162377A0 (en) | 2005-11-20 |
| KR20040068286A (ko) | 2004-07-30 |
| AU2002352425A1 (en) | 2003-06-30 |
| DE60218340T2 (de) | 2007-11-29 |
| ES2280599T3 (es) | 2007-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA04005990A (es) | Derivados de 5,6-diaril-pirazina-2-amida como antagonistas de cb1. | |
| TW200507839A (en) | Therapeutic agents | |
| TW200503692A (en) | Therapeutic agents | |
| HK1050894A1 (en) | Aryl fused azapolycyclic compounds | |
| WO2004020431A3 (en) | Novel benzoimidazole derivatives useful as antiproliferative agents | |
| HUP0402150A2 (hu) | A CB1 jelzésű kannabinoid receptorra nézve agonista, parciális agonista vagy antagonista hatású 1H-imidazol-származékok, eljárás az előállításukra, azokat tartalmazó gyógyszerkészítmények és alkalmazásuk gyógyszerkészítmények előállítására | |
| DK0590919T3 (da) | Terapeutiske midler mod Parkinsons sygdom | |
| RS107504A (en) | Benzofused heteroaryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compostions including the same, and methods for their use | |
| NZ330118A (en) | Thiophenopyrimidines, pharmaceutical compositions thereof and use in treating endocrine, psychiatric and neurologic conditions | |
| MY119542A (en) | Therapeutic biaryl derivatives | |
| HUT70154A (en) | 5-ht4 receptor antagonists and pharmaceutical compositions containing them | |
| HK1094191A1 (en) | Phenyl-carboxamide compounds useful for treating pain | |
| WO2002089782A3 (en) | Dioxanes and uses thereof | |
| HK1049837A1 (en) | Amide compounds and use thereof | |
| BG104983A (en) | Aryl fused azapolycyclic compounds | |
| HU9501026D0 (en) | Oxopyridinylquinoxaline derivative | |
| CA2345069A1 (en) | 2-phenylpyran-4-one derivatives | |
| DE60216610D1 (de) | Verwendung von kondensierten Pyrazolverbindungen für die Herstellung eines Arzneimittels zur Behandlung von Bluthochdruck | |
| WO2005051953A3 (en) | Pyrrolo-pyrazine derivatives useful as cb1-modulators |